| Unique ID issued by UMIN | UMIN000055048 |
|---|---|
| Receipt number | R000062887 |
| Scientific Title | A systematic review of the skin moisturizing effects of Astaxanthin. |
| Date of disclosure of the study information | 2024/07/23 |
| Last modified on | 2024/07/23 11:16:26 |
A systematic review of the skin moisturizing effects of Astaxanthin.
A systematic review of the skin moisturizing effects of Astaxanthin.
A systematic review of the skin moisturizing effects of Astaxanthin.
A systematic review of the skin moisturizing effects of Astaxanthin.
| Japan |
Persons not suffering from any disease (excluding persons under 18 years of age, pregnant or nursing mothers)
| Not applicable | Adult |
Others
NO
To evaluate the effect of astaxanthin intake on skin moisture.
Efficacy
The primary outcome will evaluate the ability to help protect skin moisture. The effect on skin moisture will be evaluated. Specifically, Skin moisture content and Transepidermal water loss are used as endpoints, and both outcomes will be evaluated comprehensively.
Others,meta-analysis etc
| 18 | years-old | <= |
| Not applicable |
Male and Female
A systematic literature search is performed through scientific and clinical trial registries databases.
The selection criteria are as follows.
P-Persons not suffering from any disease (excluding persons under 18 years of age, pregnant or nursing mothers)
I-Intervention: Oral intake of astaxanthin-containing foods (tablets, capsules, granules, beverages, foods). Compositions containing other ingredients (compositions that also contain ingredients other than astaxanthin as the test substance are excluded.) Combination compositions with other ingredients (compositions that contain ingredients other than astaxanthin as the test substance will be excluded). Astaxanthin intake should be between 0.4 and 30 mg/day.
C-Control: The comparison control will be the consumption of a placebo food that does not contain the relevant functional substances.
O-Outcome: The primary outcome will evaluate the ability to help protect skin moisture. The effect on skin moisture will be evaluated. Specifically, Skin moisture content and Transepidermal water loss are used as endpoints, and both outcomes will be evaluated comprehensively.
S-Study design: Randomized, quasi-randomized, and non-randomized controlled trials (parallel group or crossover controlled trials) will be included.
Studies which do not meet the key inclusion criteria will be excluded.
| 1st name | Shinobu |
| Middle name | |
| Last name | Seki |
FUJIFILM Corporation
Consumer Healthcare Business Div.
106-8620
26-30, Nishiazabu 2-chome, Minato-ku, Tokyo, Japan
080-1339-9052
shinobu.seki@fujifilm.com
| 1st name | Yuriko |
| Middle name | |
| Last name | Oda |
FUJIFILM Corporation
Consumer Healthcare Business Div.
106-8620
26-30, Nishiazabu 2-chome, Minato-ku, Tokyo, Japan
090-2547-9721
Yuriko.oda@fujifilm.com
FUJIFILM Corporation
None
Self funding
Yakujihou Marketing Jimusho Co., Ltd.
N/A
N/A
N/A
N/A
NO
| 2024 | Year | 07 | Month | 23 | Day |
Unpublished
Preinitiation
| 2024 | Year | 07 | Month | 23 | Day |
| 2024 | Year | 07 | Month | 24 | Day |
| 2025 | Year | 12 | Month | 31 | Day |
This research review will be conducted in accordance with PRISMA 2020.
| 2024 | Year | 07 | Month | 23 | Day |
| 2024 | Year | 07 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000062887